Molecular therapy for Pulmonary Hypertension: Argonaute-2 (Ago-2) inhibits pulmonary hypertension via down regulation of its target genes, 23/January/2015, 22.11

Molecular therapy for Pulmonary Hypertension: Argonaute-2 (Ago-2) inhibits pulmonary hypertension via down regulation of its target genes, 23/January/2015, 22.11

Molecular therapy for Pulmonary Hypertension: Argonaute-2 (Ago-2) inhibits pulmonary hypertension via down regulation of its target genes, 23/January/2015, 22.11 150 150

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Molecular therapy for Pulmonary Hypertension: Argonaute-2 (Ago-2) inhibits pulmonary hypertension via down regulation of its target genes, 23/January/2015, 22.11, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that Argonaute-2, by increasing the expression of its target genes, it may inhibit the development of pulmonary hypertension. Thus, pharmacological formulations encompassing “Argonaute-2  activators”  may be used to treat pulmonary hypertension.

Amount: $ 300

Undisclosed information: How Argonaute-2 inhibits the development of pulmonary hypertension

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org